Diverticulitis Disease Global Market Report 2024

The global diverticulitis disease market has grown rapidly in recent years. It will grow from $1.68 billion in 2023 to $1.85 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to aging population, dietary habits, obesity, advancements in medical imaging.

The global diverticulitis disease market is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to colonoscopy and endoscopy, increased awareness, minimally invasive procedures, personalized medicine. Major trends in the forecast period include preventive measures, enhanced diagnostic tools, collaborative care models, healthcare policy changes.

The increasing need for drugs and treatments for digestive disorders is projected to be a significant factor propelling the expansion of the diverticulitis disease market in the foreseeable future. Digestive disorders encompass a broad spectrum of conditions affecting the digestive system, responsible for the breakdown and absorption of nutrients from food. These disorders, including colorectal cancer, can heighten the risk of diverticulitis by contributing to the formation of diverticula and fostering bacterial stagnation in the colon's pouches. For instance, as of September 2022, the International Agency for Research on Cancer estimated that by 2040, there would be an annual occurrence of 3.2 million new cases and 1.6 million deaths attributed to colorectal cancer, signifying a notable increase from 1.9 million newly diagnosed patients and 930,000 deaths in 2020. Consequently, the rising demand for drugs and treatments for digestive disorders serves as a driving force behind the growth of the diverticulitis disease market.

The escalating prevalence of inflammatory bowel diseases (IBD) is anticipated to be a significant driver for the growth of the diverticulitis disease market in the coming years. Inflammatory bowel disease refers to a group of chronic inflammatory disorders primarily impacting the gastrointestinal (GI) tract. It is noteworthy that diverticulitis can initially present symptoms akin to IBD, and there is evidence of low-grade chronic inflammation in individuals with diverticula. The prevailing theory is that diverticulitis arises from mucosal inflammation induced by immune system activation. For instance, as reported by BioMed Central Ltd. in May 2021, it is projected that between 2020 and 2035, there will be an estimated 69 thousand cases of inflammatory bowel disease in Iran, 220 thousand cases in the Middle East, 2.2 million cases in India, and 4.5 million cases in East Asia. Consequently, the increasing incidence of inflammatory bowel diseases is a key driver behind the growth of the diverticulitis disease market.

Major players in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

A deficit in disease awareness is expected to impede the growth of the diverticulitis disease market in the coming years. Insufficient knowledge about diverticulitis among the general population can lead to delayed diagnosis and treatment, potentially exacerbating the condition. For example, as of June 2023, the National Library of Medicine reported that individuals experiencing symptoms like pain in the lower left abdomen, fever, nausea and vomiting, diarrhea, and loss of appetite often delay seeking care due to feelings of embarrassment or a fear of potentially undergoing gastrointestinal surgery with a colostomy bag as their sole treatment option. Consequently, the lack of awareness about the disease acts as a hindrance to the growth of the diverticulitis disease market.

Prominent companies in the diverticulitis disease market are actively engaged in the development of innovative drugs and securing regulatory approvals, a strategic move to bolster their market position. This endeavor holds the potential to yield more effective treatment options for diverticulitis, thereby mitigating the risk of complications and enhancing patient outcomes. For example, in April 2023, the United States Food and Drug Administration, a federal organization based in the US, granted approval for Seres' microbiota drug tailored for recurrent gut infections. This drug is designed to address recurring gut infections and preempt the resurgence of Clostridioides difficile (C. diff.) infections in adults aged 18 and above.

Surge In Healthcare Expenditure Drives Advancements In Diverticulitis Disease Care

North America was the largest region in the diverticulitis disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diverticulitis disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The disease is categorized into two main types sush as uncomplicated and complicated. Uncomplicated diverticulitis refers to the inflammation or infection of these small pouches, known as diverticula, within the colon walls. Various diagnostic methods such as computed tomography (CT) scans, ultrasounds, urine tests, and blood tests are employed. Treatment options encompass medications, surgery, supportive care, penicillin antibiotics, other antibiotics, dietary supplements, and intravenous (IV) fluids. These treatments are utilized by diverse end-users, including specialty centers, hospitals, and research centers.

This report provides diverticulitis disease market statistics, including diverticulitis disease industry global market size, regional shares, competitors with a diverticulitis disease market share, detailed diverticulitis disease market segments, market trends and opportunities and any further data you may need to thrive in the diverticulitis disease industry. This diverticulitis disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diverticulitis disease market consists of revenues earned by entities by providing diagnostic services, pain management, nutritional therapy and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diverticulitis disease market also includes sales of antibiotics, dietary supplements, high-fiber foods and pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.